Biologics CDMO Market
完整報告名稱與涵蓋範圍
Biologics CDMO Market Size, Share & Trends Analysis Report, By Product (Monoclonal Antibodies, Recombinant Proteins, Vaccines, Antibody Drug Conjugates, Cell & Gene Therapies, Other Biologics), By Service (Process Development, Drug Substance Manufacturing, Fill Finish & Drug Product, Analytical & Quality Services), By Scale of Operation (Preclinical & Clinical, Commercial), By Expression System, By Region, and Segment Forecasts, 2026-2035
報告摘要
The biologics CDMO market covers contract development and manufacturing organisations that supply process development, drug substance production, fill finish and analytical services for protein and advanced therapies on behalf of innovator and biosimilar sponsors. The scope spans monoclonal antibodies, recombinant proteins, vaccines, antibody drug conjugates and cell and gene therapies, produced in mammalian and microbial expression systems at clinical through commercial scale, but excludes small molecule contract manufacturing.
Outsourcing intensity keeps rising because biomanufacturing capital costs are prohibitive for most emerging biotechs, whose pipelines now account for a large share of clinical-stage molecules yet who rarely build stainless steel or single-use capacity of their own. Large pharmaceutical companies are also externalising bispecific antibody and conjugate programmes that require specialised high-potency handling and conjugation suites. Structural trends include the shift toward single-use bioreactors and intensified or continuous processing that raise titres and shorten changeovers, the build-out of dedicated ADC and viral vector suites, and geopolitical reshoring of capacity to the United States and Europe in response to supply chain security legislation affecting reliance on Chinese service providers.
North America and Europe lead demand on the strength of their innovator pipelines, while South Korea, China, Japan and India are expanding aggressively as capacity hubs. Competition is moderately consolidated around a handful of multinationals with global networks, flanked by specialised mid-size players competing on niche modalities and speed.
The InsightAce study delivers revenue forecasts in US$ across all product, service, scale, expression system and regional segments for 2026-2035, together with segment-level trend analysis, competitive landscape assessment and detailed company profiling.
授權報價
| Single User | $4,500 USD |
| Enterprise / Global Site Licence | $9,500 USD |
目錄 Table of Contents
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Biologics CDMO Market Snapshot
Chapter 4. Global Biologics CDMO Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Market Drivers
4.3. Market Challenges
4.4. Emerging Trends
4.5. Investment and Funding Analysis
4.6. Industry Analysis - Porter's Five Forces Analysis
4.7. Competitive Landscape and Market Positioning
4.8. Market Opportunity Analysis
Chapter 5. Market Segmentation 1: By Product Estimates & Trend Analysis
5.1. Product & Market Share, 2026 & 2035
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analysis, 2026 to 2035, by Product:
5.2.1. Monoclonal Antibodies
5.2.2. Recombinant Proteins
5.2.3. Vaccines
5.2.4. Antibody Drug Conjugates
5.2.5. Cell & Gene Therapies
5.2.6. Other Biologics
Chapter 6. Market Segmentation 2: By Service Estimates & Trend Analysis
6.1. Service & Market Share, 2026 & 2035
6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analysis, 2026 to 2035, by Service:
6.2.1. Process Development
6.2.2. Drug Substance Manufacturing
6.2.3. Fill Finish & Drug Product
6.2.4. Analytical & Quality Services
Chapter 7. Market Segmentation 3: By Scale of Operation Estimates & Trend Analysis
7.1. Scale of Operation & Market Share, 2026 & 2035
7.2. Market Size (Value US$ Mn) & Forecasts and Trend Analysis, 2026 to 2035, by Scale of Operation:
7.2.1. Preclinical & Clinical
7.2.2. Commercial
Chapter 8. Market Segmentation 4: By Expression System Estimates & Trend Analysis
8.1. Expression System & Market Share, 2026 & 2035
8.2. Market Size (Value US$ Mn) & Forecasts and Trend Analysis, 2026 to 2035, by Expression System:
8.2.1. Mammalian
8.2.2. Microbial
8.2.3. Others
Chapter 9. Biologics CDMO Market: Regional Estimates & Trend Analysis
9.1. North America
9.1.1. United States
9.1.2. Canada
9.2. Europe
9.2.1. Germany
9.2.2. United Kingdom
9.2.3. France
9.2.4. Italy
9.2.5. Spain
9.2.6. Rest of Europe
9.3. Asia Pacific
9.3.1. China
9.3.2. Japan
9.3.3. India
9.3.4. South Korea
9.3.5. Australia
9.3.6. Southeast Asia
9.3.7. Rest of Asia Pacific
9.4. Latin America
9.4.1. Brazil
9.4.2. Mexico
9.4.3. Rest of Latin America
9.5. Middle East & Africa
9.5.1. GCC Countries
9.5.2. South Africa
9.5.3. Rest of Middle East & Africa
Chapter 10. Competitive Landscape
10.1. Company Market Positioning Analysis
10.2. Strategic Developments (Partnerships, Expansions, Product Launches, M&A)
Chapter 11. Company Profiles
11.1. Lonza Group AG
11.2. Samsung Biologics
11.3. WuXi Biologics
11.4. Boehringer Ingelheim BioXcellence
11.5. Fujifilm Diosynth Biotechnologies
11.6. Catalent Inc. (Novo Holdings)
11.7. Thermo Fisher Scientific Inc.
11.8. AGC Biologics
11.9. Rentschler Biopharma SE
11.10. KBI Biopharma Inc.
11.11. Wacker Biotech GmbH
11.12. ProBioGen AG
11.13. Binex Co. Ltd.
11.14. Cytovance Biologics
圖表清單 List of Tables & Figures
Table 1. Global Biologics CDMO Revenue Forecast by Product, 2026-2035 (US$ Mn)
Figure 1. Global Biologics CDMO Market Segmentation Overview
Table 2. Global Biologics CDMO Revenue Forecast by Service, 2026-2035 (US$ Mn)
Figure 2. Monoclonal Antibody Contract Manufacturing Demand Outlook
Table 3. Global Biologics CDMO Revenue Forecast by Scale of Operation, 2026-2035 (US$ Mn)
Figure 3. Global Biologics CDMO Share by Expression System, 2026 & 2035
Table 4. Global Biologics CDMO Revenue Forecast by Expression System, 2026-2035 (US$ Mn)
Figure 4. Single-Use and Continuous Bioprocessing Adoption Trends in Contract Manufacturing
Table 5. North America Biologics CDMO Revenue by Country, 2026-2035 (US$ Mn)
Figure 5. Global Installed Biomanufacturing Capacity Landscape by Region
Table 6. Europe Biologics CDMO Revenue by Country, 2026-2035 (US$ Mn)
Figure 6. Asia Pacific Biologics CDMO Growth Opportunity Analysis
Table 7. Asia Pacific Biologics CDMO Revenue by Country, 2026-2035 (US$ Mn)
Figure 7. Competitive Positioning of Key Biologics CDMO Participants
Table 8. Recent Capacity Expansions and M&A Among Biologics CDMOs
Figure 8. Antibody Drug Conjugate and Cell & Gene Therapy Outsourcing Trend Analysis
提及公司
常見問題
這份報告可以先索取樣本嗎？
可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。
報告價格如何計算？
報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。
下單後多久交付？如何付款？
一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。
量子訊息有限公司為 InsightAce Analytic 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們